| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf4ae3c2c3f0ded6a5670c515121fd8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd7e2d3813c2c5d4b4782657b3ddd39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff476bb2370dc7f6275a189bff922097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b7ac4c39167cc78f276a5e6088babed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90bdd3287688eb3c00e3b10a6877fb97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7952859993227b8313007d7801390d53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fcdb6ea3eadd64c64bf11be8ecf0dd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12689d033b0724e2147b352a2c215948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc3c2078b2f271f7221aee149e5e405f |
| publicationDate |
2007-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006105439-A3 |
| titleOfInvention |
Susceptibility gene for myocardial infarction, stroke. and paod; methods of treatment |
| abstract |
Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8710081-B2 |
| priorityDate |
2005-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |